NEW YORK August 4, 2025 Noom, the leading digital healthcare company committed to chronic disease prevention and empowering people to live better longer, today announced the launch of the Noom Microdose GLP-1 Rx Program, a groundbreaking offering designed to unlock weight loss and long-term health benefits while minimizing side effects through personalized microdoses of GLP-1 medication, when clinically appropriate
Both are injectable peptide-based therapies targeting multiple hormonal pathways cagrilintide as a long-acting amylin analogue, and retatrutide as a triple receptor agonist acting on GLP-1, GIP, and glucagon receptors
Patients seeking medical weight loss services in Dallas can benefit from a comprehensive approach that addresses the underlying factors affecting weight gain and weight management
Estudios clnicos han demostrado que permiten perder al menos un 5 % del peso corporal, y muchos pacientes logran reducciones mayores, especialmente si combinan el tratamiento con dieta y ejercicio
A Phase 2a trial (NCT06850727) organized as a two-part, open-label and randomized study evaluating the safety and efficacy of OD-07656 followed by vedolizumab therapy in patients with moderately to severely active UC, with primary outcomes measuring changes in the 3-component mMS from baseline to 12 weeks and treatment-emergent AEs
Major cardiovascular outcomes trials such as SUSTAIN-6 and PIONEER-6 included patients with various comorbidities, but did not specifically report outcomes in autoimmune disease subgroups, representing a knowledge gap in this area